

## Medicine summary -doxepin (to end January 2009)

			Case Group	Death Outcomes	Sole
Case Count			<b>466</b>	<b>6</b>	<b>251</b>
Reaction Count	Blood and lymphatic system disorders	Anaemia	1	0	0
		Aplastic anaemia	2	2	0
Bone marrow failure		1	0	1	
Pancytopenia		4	0	1	
Haemolytic anaemia		1	0	1	
Coombs positive haemolytic anaemia		1	0	0	
Thrombocytopenia		7	0	3	
Eosinophilia		1	0	0	
Leukocytosis		1	0	0	
Leukopenia		6	0	2	
Lymphopenia		3	0	2	
Agranulocytosis		2	0	1	
Neutropenia		8	0	2	
		<b>Blood and lymphatic system disorders</b>	<b>38</b>	<b>2</b>	<b>13</b>
		Cardiac disorders	Arrhythmia	1	1
	Bradycardia		3	0	0
	Extrasystoles		2	0	1
	Tachycardia		10	0	5
	Atrial fibrillation		2	0	1
	Supraventricular tachycardia		1	0	0
	Ventricular tachycardia		1	0	0
	Palpitations		5	0	4
	Coronary artery thrombosis		1	0	0
	Myocardial infarction		1	1	0
	Cardiomyopathy		1	0	1
	<b>Cardiac disorders</b>		<b>28</b>	<b>2</b>	<b>12</b>
	Congenital, familial and genetic disorders	Congenital hand malformation	1	0	0
		<b>Congenital, familial and genetic disorders</b>	<b>1</b>	<b>0</b>	<b>0</b>
	Ear and labyrinth disorders	Deafness	1	0	1
		Hyperacusis	1	0	1
		Tinnitus	7	0	5
		Vertigo	3	0	1
		<b>Ear and labyrinth disorders</b>	<b>12</b>	<b>0</b>	<b>8</b>
	Endocrine disorders	Inappropriate antidiuretic hormone secretion	1	0	0
		<b>Endocrine disorders</b>	<b>1</b>	<b>0</b>	<b>0</b>
	Eye disorders	Cataract	1	0	0
		Eye pain	1	0	1
		Glaucoma	3	0	3
		Conjunctivitis	2	0	1
		Oculogyric crisis	1	0	1
		Mydriasis	1	0	0

**Medicine summary -doxepin (to end January 2009)**

			Case Group	Death Outcomes	Sole
Reaction Count	Eye disorders	Photophobia	2	0	1
		Blindness	1	0	0
		Chromatopsia	1	0	1
		Diplopia	2	0	1
		Visual impairment	12	0	8
		<b>Eye disorders</b>	<b>27</b>	<b>0</b>	<b>17</b>
	Gastrointestinal disorders	Dental caries	1	0	0
		Toothache	1	0	0
		Tooth discolouration	1	0	0
		Gingival atrophy	1	0	0
		Gingivitis	1	0	1
		Pancreatitis	1	0	0
		Haematemesis	1	0	0
		Melaena	3	0	0
		Gastritis	1	0	1
		Oesophagitis	4	0	2
		Diarrhoea	5	0	4
		Constipation	12	0	7
		Dyspepsia	6	0	4
		Eructation	1	0	1
		Flatulence	2	0	2
		Abdominal pain	7	0	3
		Breath odour	1	0	0
		Dysphagia	2	0	1
		Nausea	16	0	9
		Vomiting	9	0	2
		Ileus	1	0	1
		Duodenal ulcer	1	0	0
		Gastric ulcer	2	0	0
		Gastric ulcer haemorrhage	1	0	0
		Oesophagitis ulcerative	1	0	0
		Malabsorption	1	0	0
		Mouth ulceration	2	0	1
		Retroperitoneal fibrosis	2	0	0
Dry mouth	16	0	12		
Glossitis	1	0	1		
<b>Gastrointestinal disorders</b>	<b>104</b>	<b>0</b>	<b>52</b>		
General disorders and administration site conditions	Hyperthermia malignant	1	0	0	
	Hyperpyrexia	1	0	0	
	Pyrexia	9	0	1	
	Sudden death	1	1	0	
	Asthenia	4	0	2	

**Medicine summary -doxepin (to end January 2009)**

			Case Group	Death Outcomes	Sole	
Reaction Count	General disorders and administration site conditions	Fatigue	7	0	3	
		Malaise	6	0	4	
		Gait disturbance	4	0	2	
		Mucosal inflammation	1	0	0	
		Face oedema	6	0	2	
		Generalised oedema	1	0	1	
		Gravitational oedema	2	0	1	
		Oedema	4	0	4	
		Oedema peripheral	6	0	6	
		Chest pain	2	0	1	
		Pain	3	0	2	
		Chills	3	0	0	
		Feeling hot	1	0	1	
		Drug ineffective	4	0	3	
		Therapeutic response decreased	1	0	0	
		Drug withdrawal syndrome neonatal	1	0	0	
		<b>General disorders and administration site conditions</b>	<b>68</b>	<b>1</b>	<b>33</b>	
		Hepatobiliary disorders	Hepatitis cholestatic	2	0	1
			Jaundice	9	1	3
Hepatic function abnormal	14		0	2		
Hepatomegaly	2		0	0		
Hepatic steatosis	1		0	1		
Hepatitis	10		0	3		
Hepatocellular injury	1		0	1		
<b>Hepatobiliary disorders</b>	<b>39</b>		<b>1</b>	<b>11</b>		
Infections and infestations	Sepsis	2	1	0		
	Nasopharyngitis	1	0	1		
	Pharyngitis	2	0	1		
	Rhinitis	1	0	1		
	<b>Infections and infestations</b>	<b>6</b>	<b>1</b>	<b>3</b>		
Injury, poisoning and procedural complications	Medication error	1	0	0		
	<b>Injury, poisoning and procedural complications</b>	<b>1</b>	<b>0</b>	<b>0</b>		
Investigations	Blood pressure increased	1	0	0		
	Blood creatine phosphokinase increased	2	0	0		
	Blood alkaline phosphatase increased	1	0	1		
	Prothrombin level decreased	1	0	0		
	Red blood cell sedimentation rate increased	1	0	0		
	Weight decreased	2	1	0		
	Weight increased	16	0	13		
	<b>Investigations</b>	<b>24</b>	<b>1</b>	<b>14</b>		

**Medicine summary -doxepin (to end January 2009)**

			Case Group	Death Outcomes	Sole
Reaction Count	Metabolism and nutrition disorders	Decreased appetite	6	0	3
		Increased appetite	4	0	3
		Feeding disorder neonatal	1	0	0
		Hyperkalaemia	2	0	0
		Hypokalaemia	3	0	0
		Hypernatraemia	1	0	0
		Hyponatraemia	13	0	6
		Dehydration	1	0	0
		Hyperglycaemia	3	0	1
		Hypoglycaemia	1	0	1
		Hyperuricaemia	2	0	1
		<b>Metabolism and nutrition disorders</b>	<b>37</b>	<b>0</b>	<b>15</b>
		Musculoskeletal and connective tissue disorders	Arthralgia	5	0
	Osteoarthritis		1	0	1
	Myalgia		8	0	5
	Muscle spasms		3	0	2
	Muscle twitching		4	0	3
	Muscle rigidity		1	0	0
	Musculoskeletal stiffness		1	0	0
	<b>Musculoskeletal and connective tissue disorders</b>		<b>23</b>	<b>0</b>	<b>16</b>
	Nervous system disorders	Encephalopathy	2	0	0
		Headache	17	0	15
		Dementia	1	0	0
		Amnesia	3	0	1
		Choreoathetosis	1	0	0
		Dyskinesia	2	0	0
		Extrapyramidal disorder	1	0	0
		Hyperkinesia	4	0	3
		Hypokinesia	2	0	0
		Tardive dyskinesia	1	0	0
		Dystonia	3	0	1
		Hemiparesis	1	0	1
		Paresis	1	0	1
		Parkinsonian rest tremor	1	0	0
		Parkinsonism	1	0	0
		Tremor	19	0	10
		Hyperreflexia	1	0	0
Ataxia		14	0	9	
Cerebellar syndrome		2	0	1	
Coordination abnormal		4	0	3	
Coma	2	0	0		

**Medicine summary -doxepin (to end January 2009)**

			Case Group	Death Outcomes	Sole	
Reaction Count	Nervous system disorders	Aphasia	1	0	0	
		Consciousness fluctuating	1	0	0	
		Depressed level of consciousness	1	0	1	
		Somnolence	16	0	11	
		Stupor	3	0	2	
		Syncope	7	0	2	
		Clonus	2	0	0	
		Dizziness	15	0	11	
		Hyperaesthesia	1	0	1	
		Paraesthesia	8	0	6	
		Ageusia	1	0	1	
		Dysgeusia	5	0	1	
		Hypoaesthesia	2	0	2	
		Sensory disturbance	1	0	0	
		Speech disorder	3	0	1	
		Anticholinergic syndrome	1	0	0	
		Autonomic nervous system imbalance	1	0	0	
		Hypertonia	7	0	2	
		Neuroleptic malignant syndrome	1	0	0	
		Serotonin syndrome	3	0	0	
		Myasthenic syndrome	1	0	1	
		Neuritis	1	0	1	
		Neuropathy peripheral	1	0	1	
		Grand mal convulsion	4	0	2	
		Convulsion	9	0	2	
		Drug withdrawal convulsions	1	0	0	
		<b>Nervous system disorders</b>	<b>180</b>	<b>0</b>	<b>93</b>	
		Psychiatric disorders	Agitation	19	0	10
			Anxiety	7	0	3
			Nervousness	7	0	6
			Restlessness	1	0	0
			Bruxism	1	0	1
			Confusional state	21	0	7
			Disorientation	1	0	0
Delirium	3		0	1		
Depression	6		1	2		
Depersonalisation	2		0	2		
Delusion	1		0	0		
Hallucination	12		0	6		
Hallucination, visual	1		0	0		
Thinking abnormal	2		0	2		
Affect lability	2		0	1		

**Medicine summary -doxepin (to end January 2009)**

			Case Group	Death Outcomes	Sole
Reaction Count	Psychiatric disorders	Aggression	4	0	2
		Paranoia	4	0	0
		Personality disorder	1	0	1
		Withdrawal syndrome	7	0	4
		Psychotic disorder	5	0	1
		Schizophreniform disorder	1	0	0
		Libido decreased	2	0	2
		Insomnia	18	0	15
		Nightmare	16	0	13
		Sleep disorder	1	0	0
		Conversion disorder	1	0	1
		Suicide attempt	1	1	0
		<b>Psychiatric disorders</b>	<b>147</b>	<b>2</b>	<b>80</b>
	Renal and urinary disorders	Tubulointerstitial nephritis	1	0	0
		Anuria	1	0	0
		Renal failure acute	3	0	0
		Renal impairment	4	0	0
		Micturition disorder	1	0	1
		Pollakiuria	2	0	1
		Urinary incontinence	1	0	1
		Urinary retention	4	0	1
		Renal pain	1	0	1
		<b>Renal and urinary disorders</b>	<b>18</b>	<b>0</b>	<b>5</b>
	Reproductive system and breast disorders	Breast enlargement	3	0	3
		Breast mass	1	0	0
		Gynaecomastia	3	0	2
		Breast pain	4	0	3
		Galactorrhoea	3	0	2
		Suppressed lactation	3	0	3
		Cervix disorder	1	0	0
		Menorrhagia	1	0	1
		Ejaculation failure	1	0	0
		Erectile dysfunction	5	0	3
		Testicular disorder	1	0	1
		Vulval disorder	1	0	1
		<b>Reproductive system and breast disorders</b>	<b>27</b>	<b>0</b>	<b>19</b>
	Respiratory, thoracic and mediastinal disorders	Bronchospasm	1	0	1
		Pulmonary fibrosis	1	0	0
		Pleural effusion	1	0	0
		Dyspnoea	2	0	1
		Respiratory depression	1	0	1
		Hypoxia	1	1	0

**Medicine summary -doxepin (to end January 2009)**

			Case Group	Death Outcomes	Sole
Reaction Count	Respiratory, thoracic and mediastinal disorders	Cough	2	0	1
		Haemoptysis	1	0	0
		Respiratory failure	1	0	0
		Respiratory disorder	2	0	1
		Epistaxis	2	0	2
		<b>Respiratory, thoracic and mediastinal disorders</b>	<b>15</b>	<b>1</b>	<b>7</b>
	Skin and subcutaneous tissue disorders	Angioedema	3	0	1
		Periorbital oedema	1	0	0
		Urticaria	13	0	5
		Skin hypertrophy	1	0	0
		Dermatitis bullous	2	0	0
		Erythema multiforme	5	0	3
		Pemphigoid	1	0	0
		Dermatitis	2	0	2
		Eczema	2	0	1
		Rash erythematous	9	0	4
		Skin exfoliation	1	0	0
		Photosensitivity reaction	13	0	7
		Pruritus	15	0	5
		Psoriasis	2	0	1
		Rash	18	0	5
		Rash maculo-papular	11	0	7
		Rash morbilliform	2	0	1
		Systemic lupus erythematosus rash	1	0	0
		Acne	2	0	0
		Alopecia	4	0	2
		Hyperhidrosis	20	0	9
		Hair texture abnormal	1	0	1
		Seborrhoea	1	0	1
		Purpura	8	0	4
	<b>Skin and subcutaneous tissue disorders</b>	<b>138</b>	<b>0</b>	<b>59</b>	
	Vascular disorders	Circulatory collapse	1	0	0
		Hypotension	5	0	1
Orthostatic hypotension		10	0	5	
Flushing		3	0	1	
Hot flush		1	0	1	
Hypertension		3	0	3	
<b>Vascular disorders</b>		<b>23</b>	<b>0</b>	<b>11</b>	
<b>Reaction</b>	<b>957</b>	<b>11</b>	<b>468</b>		